Predictive implications of decreased CA19‐9 at 8 weeks during nab‐paclitaxel plus gemcitabine for the induction of second‐line chemotherapy for patients with advanced pancreatic cancer

BACKGROUND: Second‐line (2L) chemotherapy after nab‐paclitaxel plus gemcitabine (AG) is important for improving the survival of patients with advanced pancreatic cancer (APC). However, many patients fail to receive 2L chemotherapy because of rapid disease progression. Therefore, early recognition of...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Rep (Hoboken)
Egile Nagusiak: Iede, Kiyotsugu, Yamada, Terumasa, Kato, Ryo, Ueda, Masami, Tsuda, Yujiro, Nakashima, Shinsuke, Ohta, Katsuya, Matsuyama, Jin, Ikenaga, Masakazu, Tominaga, Shusei
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7941508/
https://ncbi.nlm.nih.gov/pubmed/32969199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cnr2.1289
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak